Nu Young (Cure Cell)

The corporate existence of Nu Young is well established: the Indian company registry documents Nu Young Marketing Private Limited (CIN U47720PB2025PTC063786), incorporated March 2025, status Active, with named directors [web:indiafilings.com][web:falconebiz.com]. That confirms a real registered entity — it does not, on its own, validate the income opportunity or the product claims.

Several factors warrant caution:

• Disease-cure marketing vs. the product disclaimer. Promoters and the company's own plan advertise '100% results on more than 200 diseases' [web:scribd.com], while retail listings of the same product carry a standard supplement disclaimer that it is 'not intended to diagnose, treat, cure, or prevent any disease' [web:anikmart.in]. This is a direct internal contradiction, and sweeping disease-cure advertising for a supplement raises regulatory exposure of the type Indian authorities have flagged — though no regulator or court has ruled against Nu Young specifically.
• Unverified passive-return figures. The buy-in, weekly payout, and binary bonus numbers come only from the opportunity's own promotion, not from any audited or third-party-verified source [web:scribd.com].
• Unverified overseas branding. The Singapore-based 'Cure Cell Mystic Rejuvenation' presentation is not backed by any independent registry confirmation; the only verifiable entity is the small Indian company [web:inuyoung.com][web:falconebiz.com].
• Structural and operational flags. Very young company, minimal capital (~USD 1,200), a suspended primary official domain (nuyoung.org on clientHold), and no located proof of registration on India's direct-selling framework.

No enforcement action, court judgment, or regulatory ruling against Nu Young was found in available records. Readers should weigh the documented corporate identity against the unverified income and health claims and the SEC pyramid hallmarks above [web:sec.gov].

Nu Young is a direct-selling / multi-level-marketing (MLM) opportunity built around a product called Cure Cell, marketed as an apple-derived (Malus Domestica) botanical 'stem cell' powder for 'cellular renewal.' The opportunity is operated by Nu Young Marketing Private Limited, an Indian company incorporated on 6 March 2025 and registered at Zirakpur, Mohali district, Punjab 140603, under the Registrar of Companies, Chandigarh; its registry status is 'Active' [web:indiafilings.com][web:falconebiz.com].

The company is small: authorized and paid-up capital of just Rs 1,00,000 (about USD 1,200), with two listed directors, Ankush Watts (DIN 10838413) and Umesh Singhal (DIN 03565142), both appointed 9 July 2025 [web:indiafilings.com][web:thecompanycheck.com]. There is no independently verified public 'founder' figure beyond these directors; promotion is driven largely by independent distributors, concentrated in South India with heavy Telugu- and Hindi-language social-media content.

One notable operational flag: the primary advertised official domain, nuyoung.org, is currently under registry status clientHold (suspended) and does not resolve, while activity continues through the inuyoung.com portal and distributor social channels [web:inuyoung.com].

The opportunity's marketing describes an entry buy-in of about USD 62, frequently bundled as a 1+1 product offer [web:scribd.com]. This figure is drawn from promotional material rather than an audited disclosure and should be treated as indicative. Any ongoing monthly purchase or maintenance requirement is not publicly documented. Prospective participants should note that the same Cure Cell product is available on third-party marketplaces at a fraction of the network's internal pricing — roughly Rs 700 for a 40g pack [web:anikmart.in] — which is relevant when weighing the buy-in against retail product value.